JP2021514188A5 - - Google Patents

Info

Publication number
JP2021514188A5
JP2021514188A5 JP2020543746A JP2020543746A JP2021514188A5 JP 2021514188 A5 JP2021514188 A5 JP 2021514188A5 JP 2020543746 A JP2020543746 A JP 2020543746A JP 2020543746 A JP2020543746 A JP 2020543746A JP 2021514188 A5 JP2021514188 A5 JP 2021514188A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
chain variable
Prior art date
Application number
JP2020543746A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019161133A5 (https=
JP2021514188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018112 external-priority patent/WO2019161133A1/en
Publication of JP2021514188A publication Critical patent/JP2021514188A/ja
Publication of JP2021514188A5 publication Critical patent/JP2021514188A5/ja
Publication of JPWO2019161133A5 publication Critical patent/JPWO2019161133A5/ja
Abandoned legal-status Critical Current

Links

JP2020543746A 2018-02-15 2019-02-14 Foxp3標的因子組成物と養子細胞療法のための使用方法 Abandoned JP2021514188A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862631465P 2018-02-15 2018-02-15
US62/631,465 2018-02-15
PCT/US2019/018112 WO2019161133A1 (en) 2018-02-15 2019-02-14 Foxp3 targeting agent compositions and methods of use for adoptive cell therapy

Publications (3)

Publication Number Publication Date
JP2021514188A JP2021514188A (ja) 2021-06-10
JP2021514188A5 true JP2021514188A5 (https=) 2022-02-08
JPWO2019161133A5 JPWO2019161133A5 (https=) 2022-02-08

Family

ID=67618784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543746A Abandoned JP2021514188A (ja) 2018-02-15 2019-02-14 Foxp3標的因子組成物と養子細胞療法のための使用方法

Country Status (8)

Country Link
US (1) US20220267420A1 (https=)
EP (1) EP3752601A4 (https=)
JP (1) JP2021514188A (https=)
CN (1) CN112041432A (https=)
CA (1) CA3091143A1 (https=)
IL (1) IL276672A (https=)
SG (1) SG11202007697VA (https=)
WO (1) WO2019161133A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021243695A1 (en) * 2020-06-05 2021-12-09 Guangdong Tcrcure Biopharma Technology Co., Ltd. Tcr-t cell therapy targeting epstein-barr virus
WO2024100170A1 (en) * 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2025076485A1 (en) * 2023-10-05 2025-04-10 Mink Therapeutics, Inc. Novel invariant natural killer t cells and t cell engager compositions and methods of use thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US20020018783A1 (en) 1997-03-20 2002-02-14 Michel Sadelain Fusion proteins of a single chain antibody and cd28 and uses thereof
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
ES2465996T3 (es) 2006-05-25 2014-06-09 Sangamo Biosciences, Inc. Métodos y composiciones para la inactivación genética
JP5266210B2 (ja) 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド 改変開裂ハーフドメイン
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2008133938A2 (en) 2007-04-26 2008-11-06 Sangamo Biosciences, Inc. Targeted integration into the ppp1r12c locus
EP3156494B8 (en) 2008-12-04 2018-09-19 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
US8771985B2 (en) 2010-04-26 2014-07-08 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using zinc-finger nucleases
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス, インコーポレイテッド 新規のdna結合タンパク質及びその使用
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
AU2012312260B2 (en) 2011-09-21 2017-08-31 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
JP6188703B2 (ja) 2011-10-27 2017-08-30 サンガモ セラピューティクス, インコーポレイテッド Hprt遺伝子座を修飾するための方法および組成物
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
EP2906684B8 (en) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
JP6346266B2 (ja) 2013-03-21 2018-06-20 サンガモ セラピューティクス, インコーポレイテッド 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するt細胞受容体遺伝子の標的化された破壊
GB201313377D0 (en) 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
JP6553069B2 (ja) 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗wt1/hla二重特異性抗体
ES2928000T3 (es) 2014-06-06 2022-11-14 Memorial Sloan Kettering Cancer Center Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
US11673957B2 (en) 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
AU2016243026B2 (en) 2015-04-03 2022-03-31 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
CN104793542A (zh) 2015-04-17 2015-07-22 深圳市优必选科技有限公司 一种基于手机控制的机器人系统
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Prame肽專一性類t細胞受體抗體
KR20180023949A (ko) 2015-06-09 2018-03-07 메모리얼 슬로안-케터링 캔서 센터 인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제
HK1254803A1 (zh) 2015-06-23 2019-07-26 Memorial Sloan Kettering Cancer Center 新型pd -1的免疫调节剂
EP3328994A4 (en) 2015-07-31 2019-04-17 Memorial Sloan-Kettering Cancer Center CD56-Faced Antigen-Binding Proteins and Uses Thereof
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
IL299203A (en) 2015-10-13 2023-02-01 Eureka Therapeutics Inc ׂ A Delaware Corp Antibody factors specific for human differentiation group 19 and their uses
EP3842450A1 (en) 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
WO2017100428A1 (en) * 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same
US11505599B2 (en) * 2016-01-14 2022-11-22 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for Foxp3-derived peptides
AU2017225733A1 (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
JP7114490B2 (ja) * 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体(CARs)の構成およびその使用方法

Similar Documents

Publication Publication Date Title
JP7737440B2 (ja) 抗ヒトパピローマウイルス(hpv)抗原結合性タンパク質およびその使用方法
CN112638947B (zh) 用于治疗实体瘤的嵌合抗原受体细胞
JP7721500B2 (ja) Mage-a4特異性を有するキメラ抗原受容体およびそれらの使用
US20190023764A1 (en) Car having replicated binding motifs in a co-stimulatory domain
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
RU2018128462A (ru) Модифицированные клетки для иммунотерапии
JP2018526033A5 (https=)
JP2018528786A5 (https=)
JP2025156298A (ja) 抗ニューヨーク食道扁平上皮がん1(ny-eso-1)抗原結合タンパク質およびその使用方法
JP2021514188A5 (https=)
CN120917046A (zh) 新型cd19结合剂、包含所述cd19结合剂的car-t构建体及其使用方法
JP7496093B2 (ja) CARライブラリおよびscFvの製造方法
CN112940136B (zh) 一种嵌合抗原结合受体car、载体、car-t细胞、药物组合物及其应用
JPWO2019157461A5 (https=)
JPWO2021016585A5 (https=)
JPWO2019161133A5 (https=)
KR20250075563A (ko) 만성 림프구성 백혈병의 b-세포 수용체를 표적으로 하는 인간화 키메라 항원 수용체 및 이의 용도
EP4314069A1 (en) Il-13ra2 chimeric antigen receptors and methods of use
JPWO2021263211A5 (https=)
EA052454B1 (ru) Химерные антигенные рецепторы со специфичностью к mage-a4 и их применение
RU2024115283A (ru) Композиции vcar и способы применения